Go Pro
NASDAQ:NEPH

Nephros (NEPH) Stock Price, News & Analysis

Nephros logo
$4.63 -0.06 (-1.28%)
Closing price 04:00 PM Eastern
Extended Trading
$4.48 -0.15 (-3.24%)
As of 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Nephros Stock (NASDAQ:NEPH)

Advanced

Key Stats

Today's Range
$4.23
$4.70
50-Day Range
$3.13
$4.69
52-Week Range
$2.66
$6.42
Volume
10,406 shs
Average Volume
17,972 shs
Market Capitalization
$50.28 million
P/E Ratio
28.94
Dividend Yield
N/A
Price Target
$4.00
Consensus Rating
Hold

Company Overview

Nephros, Inc. is a development-stage company specializing in advanced water filtration and purification technologies for medical, laboratory, industrial and defense applications. The company’s core offering centers on proprietary hollow fiber ultrafilters designed to remove bacteria, viruses, endotoxins and particulates from water streams. These ultrafilters are used in hemodialysis systems to protect patient treatment, in pharmaceutical and laboratory environments to ensure water quality and in critical field-deployable units for military and emergency response.

The company’s product portfolio includes standalone filtration cartridges for point-of-use and point-of-entry installations in dialysis clinics and hospitals, as well as bench-top and portable water purification systems. Nephros’ Water Purification System (WPS) is engineered to meet stringent U.S. Army and World Health Organization guidelines for field use, delivering potable water from untreated sources. In parallel, the MembraPure™ brand serves pharmaceutical and biotech customers requiring laboratory-grade water for research and manufacturing.

Nephros holds FDA 510(k) clearance for its medical-grade hollow fiber filters, underpinning its role in critical patient care applications. The company distributes products directly to healthcare providers and partners with OEMs and authorized distributors to serve markets across North America and select international territories. Its technology has been adopted by hospitals seeking to safeguard dialysis water and by research institutions requiring ultrapure water for sensitive assays.

Founded in 2005 and headquartered in Kinnelon, New Jersey, Nephros operates under the leadership of President and Chief Executive Officer Hal S. Zarem. The company maintains a focus on product innovation through ongoing research and development efforts, pursuing commercial partnerships and clinical collaborations to expand its footprint in water purification and filtration solutions.

AI Generated. May Contain Errors.

Nephros Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
45th Percentile Overall Score

NEPH MarketRank™: 

Nephros scored higher than 45% of companies evaluated by MarketBeat, and ranked 605th out of 913 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Nephros has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, no buy ratings, 3 hold ratings, and no sell ratings.

  • Downside Risk

    Nephros has a consensus price target of $4.00, representing about 13.6% downside from its current price of $4.63.

  • Amount of Analyst Coverage

    Nephros has only been the subject of 3 research reports in the past 90 days.

  • Read more about Nephros' stock forecast and price target.
  • Earnings Growth

    Earnings for Nephros are expected to grow by 533.33% in the coming year, from $0.03 to $0.19 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Nephros is 28.94, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.57.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Nephros is 28.94, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 269.86.

  • Price to Book Value per Share Ratio

    Nephros has a P/B Ratio of 4.82. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.37% of the float of Nephros has been sold short.
  • Short Interest Ratio / Days to Cover

    Nephros has a short interest ratio ("days to cover") of 4.18.
  • Change versus previous month

    Short interest in Nephros has recently increased by 19.65%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Nephros does not currently pay a dividend.

  • Dividend Growth

    Nephros does not have a long track record of dividend growth.

  • News Sentiment

    Nephros has a news sentiment score of 1.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Nephros this week, compared to 1 article on an average week.
  • Search Interest

    Only 1 people have searched for NEPH on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Nephros insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    6.70% of the stock of Nephros is held by insiders.

  • Percentage Held by Institutions

    41.10% of the stock of Nephros is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Nephros' insider trading history.
Receive NEPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nephros and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

NEPH Stock News Headlines

Nephros (NEPH) Q2 2026 Earnings Call Transcript
Nephros Q2 Earnings Call Highlights
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
Nephros, Inc. (NEPH) Q2 2026 Earnings Call Transcript
Nephros Launches New HydraGuard 20" UltraFilter
See More Headlines

NEPH Stock Analysis - Frequently Asked Questions

Nephros' stock was trading at $4.88 at the beginning of the year. Since then, NEPH shares have decreased by 5.1% and is now trading at $4.63.

Nephros Inc. (NASDAQ:NEPH) announced its quarterly earnings results on Thursday, August, 6th. The company reported $0.06 EPS for the quarter, beating the consensus estimate of $0.00 by $0.06. The company had revenue of $6.02 million for the quarter, compared to analysts' expectations of $4.99 million. Nephros had a trailing twelve-month return on equity of 11.03% and a net margin of 8.38%.
Read the conference call transcript
.

Nephros' top institutional shareholders include Cornerstone Capital Inc. (1.19%), Bard Associates Inc. (1.09%), BlackRock Inc. (0.17%) and De Lisle Partners LLP (0.16%).
View institutional ownership trends
.

Shares of NEPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Nephros investors own include NVIDIA (NVDA), Broadcom (AVGO), e.l.f. Beauty (ELF), Jabil (JBL), Arista Networks (ANET), Disc Medicine (IRON) and Novo Nordisk A/S (NVO).

Company Calendar

Last Earnings
8/06/2026
Today
8/14/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Healthcare Equipment & Supplies
Sub-Industry
Healthcare Supplies
Current Symbol
NASDAQ:NEPH
CIK
1196298
Employees
30
Year Founded
1997

Price Target and Rating

High Price Target
$4.00
Low Price Target
$4.00
Potential Upside/Downside
-13.6%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
$0.16
Trailing P/E Ratio
28.94
Forward P/E Ratio
154.33
P/E Growth
N/A
Net Income
$1.19 million
Net Margins
8.38%
Pretax Margin
8.45%
Return on Equity
10.60%
Return on Assets
8.05%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.07
Quick Ratio
3.12

Sales & Book Value

Annual Sales
$18.79 million
Price / Sales
2.68
Cash Flow
$0.12 per share
Price / Cash Flow
37.39
Book Value
$1.10 per share
Price / Book
4.21

Miscellaneous

Outstanding Shares
10,860,000
Free Float
10,132,000
Market Cap
$50.28 million
Optionable
Not Optionable
Beta
1.51

Social Links

10 Best Stocks to Own - Summer 2026 Cover

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:NEPH) was last updated on 8/14/2026 by MarketBeat.com Staff.
From Our Partners